The international AIDS vaccine initiative (IAVI) in a changing landscape of vaccine development: A public/private partnership as knowledge broker and integrator

European Journal of Development Research

Volumn 19, Issue 1, 2007, Pages 100-117

  Chataway, Joanna ^a   Brusoni, Stefano ^a   Cacciatori, Eugenia ^a   Hanlin, Rebecca ^a   Orsenigo, Luigi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ECONOMIC POLICY; INNOVATION; PHARMACEUTICAL INDUSTRY; PUBLIC-PRIVATE PARTNERSHIP; SUSTAINABLE DEVELOPMENT; VACCINATION;

EID: 34250680979     PISSN: 09578811     EISSN: 17439728     Source Type: Journal    
DOI: 10.1080/09578810601144350     Document Type: Conference Paper

References (29)

1. Archibuigi, D. and Bizzarri, L. (2005) The Global Governance of Communicable Diseases: The Case of Vaccine R&D. Law and Policy, 27:1, pp. 33-51.
2. Blume, S. (2005) Lock In, the State and Vaccine development: Lessons from the History of the Polio Vaccines. Research Policy, 34:2, pp. 159-173.
3. Brusoni, S., Prencipe, A. and Pavitt, K. (2001) Knowledge Specialization, Organizational Coupling, and the Boundaries of the Firm: Why do Firms Know More Than They Make?. Administrative Science Quarterly, 46:4, pp. 597-621.
4. Chandler, A. (2005) Shaping the Industrial Century: The Remarkable Story of the Modern Chemical and Pharmaceutical Industries, Harvard University Press, Cambridge, MA
5. Chataway, J. and Smith, J. (2006) The International AIDS Vaccine Initiative: Is it Getting New Science and Technology to the World's Neglected Majority?. World Development, 34:1, pp. 16-30.
6. Chataway, J. and Smith, J. (2005) Smoke, Mirrors and Poverty: Communication, Biotechnological Innovation and Development, INNOGEN Working Paper
7. Cohen, J. (2001) Shots in the Dark: The Wayward Search for an AIDS Vaccine, W.W. Norton and Co, New York and London
8. Dosi, G., Freeman, C., Nelson, R., Sliverberg, G. and Soete, L. (1988) Technical Change and Economic Theory, Pinter Publishers, London and New York
9. D'Adesky, A. (2004) Moving Mountains: The Race to Treat Global AIDS, Verso, London and New York
10. Fujimura, J.H. (1992) Crafting Science: Standardised Packages, Boundary Objects and "Translation". Science as Practice and Culture, pp. 168-214. The University of Chicago Press, Chicago, IL
11. Galison, P. (1997) Image & Logic - A Material Culture of Microphysics, University of Chicago Press, Chicago, IL and London
12. Hanlon, J., Chataway, J., Mackintosh, M. and Wuyts, M. (2005) Bridging the Gulf between Policies for Innovation, Productivity and Industrial Growth and Policies to Reduce Poverty, Summary of a workshop, 18-20 November 2005
13. Hargadon, A. and Sutton, R.I. (1997) Technology Brokering and Innovation in a Product Development Firm. Administrative Science Quarterly, 42:4, pp. 716-749.
14. Henderson, R., Orsenigo, L. and Pisano, G.P. (1999) The Pharmaceutical Industry and the Revolution in Molecular Biology: Interactions Among Scientific, Institutional and Organizational Change. Sources of Industrial Leadership-Studies of Seven Industries, Cambridge University Press, Cambridge
15. IAVI (2004) 2005-2007 Strategic Plan, IAVI, New York
16. IAVI (2004) Annual Progress Report, IAVI, New York
17. IAVI (2004) Scientific Blueprint 2004, IAVI, New York
18. Kettler, H. and Towse, A. (2002) Public Private Partnerships for Research and Development: Medicines and Vaccines for Poverty, Office of Health Economics, London
19. Kremer, M. and Glennerster, R. (2004) Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases, Princeton University Press, Princeton, NJ, and Oxford
20. Latour, B. (1987) Science in Action: How to Follow Scientists and Engineers Through Society, Open University Press, Milton Keynes
21. Milstien, J. and Candries, B. (2000) Economics of Vaccine Development and Implementation: Changes Over the Past 20 Years, WHO, Geneva
22. Moran, M. (2005) A Breakthrough in R&D for Neglected Diseases: New Ways to get the Drugs we Need. Public Library of Science Medicine, 2:9, p. e302.
23. Morel, C., Acharya, T., Broun, D., Dangi, A., Elias, C., Ganguly, N.K., Gardner, C., Gupta, R.K., Haycock, J., Heher, A., Hotez, P.J., Kettler, H., Keusch, G.T., Krattiger, A.F., Kreutz, F.T., Lall, S., Keun, L., Mahoney, R., Martinez-Palomo, A., Mashelkar, R.A., Matlin, S., Mzimba, M., Oehler, J., Ridley, R.G., Senanayaka, P., Singer, P. and Yun, M. (2005) Health Innovation Networks to Help Developing Countries Address Neglected Diseases. Science, 309:5733, pp. 401-404.
24. Nelson, R. (1993) National Innovation Systems: A Comparative Analysis, Oxford University Press, New York and Oxford
25. Pavitt, K. (2000) Innovating Routines in the Business Firm: What Matters, What's Staying the Same and What's Changing, SPRU, University of Sussex, Brighton
26. Sharp, D. (2004) Not-for-profit-drugs-no Longer an Oxymoron?. The Lancet, 364:9444, pp. 1472-1474.
27. Vincenti, W. (1991) What Engineers Know and How They Know It, Johns Hopkins Press, Baltimore, MD
28. Widdus, R. and White, K. (2003) Public Private Partnerships for Health: Their Main Targets, Their Diversity and Their Future Direction, IPPPH Publications, Geneva
29. Widdus, R. and White, K. (2005) Combating Diseases Associated with Poverty. Financing Strategies for Product Development and the Potential Role of Public-private Partnerships, IPPPH Publications, Geneva